131 related articles for article (PubMed ID: 24095205)
21. Customized targeted therapy in Hodgkin lymphoma: hype or hope?
Diefenbach C; Advani R
Hematol Oncol Clin North Am; 2014 Feb; 28(1):105-22. PubMed ID: 24287071
[TBL] [Abstract][Full Text] [Related]
22. Novel agents in development for peripheral T-cell lymphoma.
O'Connor OA
Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580
[TBL] [Abstract][Full Text] [Related]
23. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
24. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
25. Is severe cardiac dysfunction a contraindication for complex combined oncotherapy of Hodgkin's lymphoma? Not any more.
Netuka I; Stepankova P; Urban M; Maly J; Szarszoi O; Dorazilova Z; Kotulak T; Pirk J
ASAIO J; 2013; 59(3):320-1. PubMed ID: 23644622
[TBL] [Abstract][Full Text] [Related]
26. The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
Beard SM; Lorigan PC; Sampson FC
Br J Cancer; 2000 Jan; 82(1):81-4. PubMed ID: 10638970
[TBL] [Abstract][Full Text] [Related]
27. Targeting cellular FLICE-like inhibitory protein as a novel approach to the treatment of Hodgkin's lymphoma.
Dutton A; Burns AT; Young LS; Murray PG
Expert Rev Anticancer Ther; 2006 Jun; 6(6):911-9. PubMed ID: 16761935
[TBL] [Abstract][Full Text] [Related]
28. [Treatment of Hodgkin lymphoma].
Tokunaga T; Nagai H
Nihon Rinsho; 2014 Mar; 72(3):538-41. PubMed ID: 24724416
[TBL] [Abstract][Full Text] [Related]
29. Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Ujjani C; Cheson BD
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1353-65. PubMed ID: 20836669
[TBL] [Abstract][Full Text] [Related]
30. Optimal treatment of premature ovarian failure after treatment for Hodgkin's lymphoma is often withheld.
Verschuuren SI; Schaap JJ; Veer MB; Stijnen T; Burger CW; Ansink AC
Acta Obstet Gynecol Scand; 2006; 85(8):997-1002. PubMed ID: 16862482
[TBL] [Abstract][Full Text] [Related]
31. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
32. [Evaluation of the small bowel in patients with Hodgkin's lymphoma during and late after chemoradiation therapy].
Khomov DA; Sinev IuV; Sotnikov VM
Vestn Rentgenol Radiol; 2008; (2-3):43-8. PubMed ID: 21337763
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
[TBL] [Abstract][Full Text] [Related]
34. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
[TBL] [Abstract][Full Text] [Related]
36. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
Friedberg JW; Cohen P; Chen L; Robinson KS; Forero-Torres A; La Casce AS; Fayad LE; Bessudo A; Camacho ES; Williams ME; van der Jagt RH; Oliver JW; Cheson BD
J Clin Oncol; 2008 Jan; 26(2):204-10. PubMed ID: 18182663
[TBL] [Abstract][Full Text] [Related]
37. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
Perz JB; Giles C; Szydlo R; O'Shea D; Sanz J; Chaidos A; Wagner S; Davis J; Loaiza S; Marin D; Apperley J; Olavarria E; Rahemtulla A; Lampert I; Naresh K; Samson D; MacDonald D; Kanfer EJ
Bone Marrow Transplant; 2007 Jan; 39(1):41-7. PubMed ID: 17115062
[TBL] [Abstract][Full Text] [Related]
38. [Bone marrow transplantation in the concept of the step-by-step therapy of refractory or recurrent Hodgkin's lymphoma].
Thomas M; Schneider W; Aul C; Heyll A
Dtsch Med Wochenschr; 1990 Oct; 115(41):1566-70. PubMed ID: 2209447
[No Abstract] [Full Text] [Related]
39. Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era.
Vitolo U; Chiappella A
Lancet Oncol; 2018 Feb; 19(2):162-163. PubMed ID: 29276023
[No Abstract] [Full Text] [Related]
40. Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma.
Connors JM; Radford JA
N Engl J Med; 2018 Apr; 378(16):1560-1561. PubMed ID: 29669231
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
